Form 4: AC Immune Director Acquires Shares and Options
Statement of Changes in Beneficial Ownership
AC Immune SA reports that Director Monika Buetler acquired 17,751 restricted share units and 41,667 share options.
Summary
- Monika Buetler, a Director at AC Immune SA, acquired 17,751 restricted share units (RSUs) on June 11, 2026, as part of the company's 2016 Stock Option and Incentive Plan (SOIP).
- Additionally, Buetler was granted share options for 41,667 shares under the same plan on June 11, 2026.
- These share options are set to fully vest on June 10, 2027.
- Following these transactions, Buetler beneficially owns 71,656 common shares, which includes 70,656 common shares underlying outstanding RSUs.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director's acquisition of equity and options, which can imply confidence, but it does not provide new financial performance data.
Positives
- Director acquisition of company stock and options can signal confidence in the company's future prospects.
- The grant of RSUs and options is part of a structured incentive plan, aligning management interests with shareholder value.
- The acquisition of 17,751 RSUs and 41,667 share options by a director indicates continued engagement and investment in the company.
Future Outlook
The filing does not contain forward-looking statements or guidance. The details pertain to a transaction of securities by a director.
Industry Context
StockSavvy.ai notes that insider transactions, such as this Form 4 filing by AC Immune SA Director Monika Buetler, are closely watched by the market as potential indicators of management's sentiment towards the company's stock. The acquisition of restricted share units and options aligns with common executive compensation practices aimed at incentivizing long-term performance.
Stakeholder Impact
- Shareholders may view the director's acquisition of equity as a positive signal of confidence in the company's future performance.
- Employees involved in the stock incentive plan may see this as a validation of the plan's structure and purpose.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Date of earliest transaction; date of RSU grant and share option grant. |
| 06/10/2027 | Full vesting date for the granted share options. |
| 06/10/2036 | Expiration date for the granted share options. |
| 06/15/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
AC Immune SA, ACIU, Form 4, Director, Restricted Share Units, Share Options, Stock Incentive Plan, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.